Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Zenas BioPharma (ZBIO) Enterprise Value (2023 - 2025)

Zenas BioPharma (ZBIO) has 3 years of Enterprise Value data on record, last reported at -$476.9 million in Q3 2025.

  • For Q3 2025, Enterprise Value fell 32.43% year-over-year to -$476.9 million; the TTM value through Sep 2025 reached -$476.9 million, down 32.43%, while the annual FY2024 figure was -$350.8 million, 516.93% down from the prior year.
  • Enterprise Value reached -$476.9 million in Q3 2025 per ZBIO's latest filing, down from -$273.3 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$37.2 million in Q1 2024 and bottomed at -$476.9 million in Q3 2025.
  • Average Enterprise Value over 3 years is -$236.0 million, with a median of -$273.3 million recorded in 2025.
  • The widest YoY moves for Enterprise Value: up 32.43% in 2025, down 738.83% in 2025.
  • A 3-year view of Enterprise Value shows it stood at -$56.9 million in 2023, then plummeted by 516.93% to -$350.8 million in 2024, then tumbled by 35.97% to -$476.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Enterprise Value were -$476.9 million in Q3 2025, -$273.3 million in Q2 2025, and -$312.4 million in Q1 2025.